TWEET by @CellCentric
Looking forward to JPM 2019, January 6-10th. More on CellCentric and its team: cellcentric.com/company/team/ pic.twitter.com/rUgwtHoV92
TWEET by @CellCentric
Cohort 2 of CCS1477’s prostate clinical trial now open. Haem study (AML, MM, NHL) to start early 2019. pic.twitter.com/eO9YlPGZxf
TWEET by @CellCentric
CCS1477 selected as a New Drug on the Horizon, AACR 2019, Atlanta. cellcentric.com/ccs1477/ pic.twitter.com/02zS0b0bD9
TWEET by @CellCentric
CCS1477: potent, selective small molecule inhibitor; clear biology MoA; for significant, specific clinical unmet needs. pic.twitter.com/U9XR8k6XMT
TWEET by @CellCentric
CCS1477 differentiation: cellcentric.com/ccs1477/differ…. First-in-class p300/CBP bromodomain inhibitor. pic.twitter.com/cqyKa9zYZ5
TWEET by @CellCentric
CCS1477, first-in-class p300/CBP bromodomain inhibitor. Differs from HAT catalytic site inhibitors. Not a BETi. pic.twitter.com/FGV8tHl7P9
